Clarity Pharma shares lift on clinical trial and new CEO
Make us a preferred source
Make us a preferred source on Google
The news: Biotech company Clarity Pharmaceuticals will start a second Phase III clinical trial of its prostate cancer diagnostic 64Cu-SAR-bisPSMA product after positive feedback from the US Food and Drug Administration, lifting its shares.
The numbers: The second trial, named AMPLIFY, will have about 220 participants and is expected to begin patient recruitment in early 2025.
Clarity Pharma shares were up nearly 4% to 47.23 in early trading on the ASX.
The context: The new Phase III clinical trial involves patients with biochemical recurrence of prostate cancer. The company is already in the process of conducting a Phase III trial involving patients with confirmed prostate cancer, named the CLARIFY trial.
Last week, it signed an agreement with US-based SpectronRx for the streamlined manufacturing process of both the 64 Cu isotope and the 64Cu-SAR-bisPSMA product for the upcoming trial.
Separately, Clarity said it has promoted head of clinical operations, Michelle Parker, to the CEO position on Friday.
She replaced Colin Biggin, who had been CEO since April 2019. Parker has been with the company for six years and has led the company’s clinical operations division. She previously led Novartis Australia’s international clinical research operations.
The sources: ASX announcement, ASX announcement
